Professor Ron Akehurst, BSc (Econ) (London), Hon MFPHM

Ron Akehurst

Professor Akehurst is an Emeritus Professor of Health Economics at the School of Health and Related Research (ScHARR)

University of Sheffield
Regent Court
30 Regent Street
Sheffield S1 4DA

Tel: (+44) (0) 114 222 5446
Fax: (+44) (0) 114 272 4095


Research Interests

All aspects of health economics; application of microeconomic theory to problems of evaluation, production and behaviour in a health context; using economic evaluative methodology to assist health care decision making; getting more health output from the clinical research base.

Teaching Interests

My teaching interests include all aspects of Health Technology Assessment (HTA), particularly in framing HTA questions to enable the appropriate design of studies and of analysis.

Activities and Distinctions

2015 – Present Honorary Professor, ELTE University, Budapest, Hungary

2013 – Present Member of the Rare Diseases Advisory Group (RDAG), NHS England

2013 – Present Member, NICE Highly Specialised Technologies Committee

2013 - 2015 Member, Alzheimer’s Society Grant Advisory Board

July 2010 - Present. Member, Advisory Group for National Specialised Services (AGNSS)

May 2010 - Present. Member, Interntional Academic Council of UdG Medicine, University of Girona

March 2010 - Present. External Assessor, National Health & Medical Research Council (NHMRC) Centres for Research Excellence Scheme (CRE), Australia

March 2010-February 2012. Member, National Institute for Health and Clinical Excellence (NICE) Diagnostics Committee

December 2009-present. Member, Innovation Research Board (IRB), Sheffield Teaching Hospitals

February 2010-present. Member, Sheffield Quality Improvement Academy Steering Group, NHS Sheffield

June 2009-present. Honorary Member, National Institute for Health Research Faculty

Sept 2008-Dec 2011. Chair, the University Senate Budget Commitee (SBC)

2007-present. Member, NICE Methods Review Workshop

2007-present. Member, NICE Single Technology Appraisal (STA) Reference Review Group

2007-present. Visting Professor, Corvinus University, Budapest

Nov 2008-Nov 2010. Member, Research Funding Board - National Institute for Health Research (NIHR) Public Health Research Programme

2007-2008. Joint Chair, Scientific Review Committee, European Conference of International Society for Pharmaeconomics and Outcomes Research, Athens

2006-2008. Member, Scientific Committe for European Conference on Health Economics, Rome

Sept 2005-June 2006. Member, Public Health Intervention Advisory Committee for the National Institute for Health and Clinical Excellence (NICE)

Dec 2006-present. Member, Health Technology Assessment International (HTAi) Scientific Committee, Barcelona

Sept 2006-present. Member, International Health Economics Association (iHEA) Scientific Committee, Copenhagen

April 2005-present. Member of the Health Services Research Network Governing Board, elected by members category

Sept 2005–June 2006. Member, Public Health Intervention Advisory Committee for the National Institute for Clinical Excellence (NICE)

2003-present. Chair, Evidence-Based Commissioning Collaboration

2002-present. Member, University of Sheffield Academic Development Committee (ADC)

2003-2006 . Member, Organising Committee for Sixth European Conference on Health Economics, Budapest, Hungary

2003-2005 . Member, Department of Health Advisory Committee for Topic Selection (ACTS) for the National Institute for Clinical Excellence (NICE)

2003-2004 . Chair, Technology Assessment Task Force for NICE Technology Appraisals Methodology Review

2003. Member, Department of Trade and Industry (DTI) and Department of Health – NHS/Industry Partnerships Working Group (BIG T)

1999-2005. Member, NICE Appraisal Committee

1999-2003 . Non-Executive Director, then Chair/Trustee: Centre for Innovation in Primary Care, Sheffield

1998–2002 . Chair, North Trent Cancer Research Network

1996-1998 . Non-executive Director, Rotherham Health Authority

1995-1997 . Specialist Advisor to the House of Commons Health Select Committee


Corvinus University, Budapest - Honorary Professor

Publications since 2005

Vivek Y. Reddy, Ronald L. Akehurst, Stacey L. Amorosi, Meghan B. Gavaghan, Deanna S. Hertz, David R. Holmes. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non–Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation. Stroke May 2018

Bjorn Stollenwerk, Sergio Iannazzo, Ron Akehurst, Michael Adena, Andrew Briggs, Bastian Dehmel, Patrick Parfrey, Vasily Belozeroff. A Decision-Analytic Model to Assess the Cost-Effectiveness
of Etelcalcetide vs. Cinacalcet. PharmacoEconomics 2018

Matthew Kurien, Elizabeth Thurgar, Ashley Davies, Ron Akehurst, Jervoise Andreyev. Challenging current views on bile acid diarrhoea and malabsorption. Frontline Gastroenterology 2017

Bertalan Németh, Anett Molnár, Ron Akehurst, Margit Horváth, Kristóf Kóczián, György Németh, Árpád Götze & Zoltán Vokó. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. Journal of Comparative Effectiveness Research 2017.

Ronald L. Akehurst, Eric Abadie, Noel Renaudin, Francois Sarkozy. Variation in Health Technology Assessment and Reimbursement Processes in Europe. Value in Health 2016

Critchlow S, Hirst M, Akehurst R, Phillips C, Philips Z, Sullivan W, Dunlop WC. A systematic review of cost-effectiveness modelling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future. Journal of Medical Economics 2016

Akehurst RL, Abadie E, Renaudin N, Sarkozy F. Variation in Health Technology Assessment and Reimbursement Processes in Europe. Value in Health 2016

Vivek Reddy; Ronald Akehurst; Meghan Gavaghan; Stacey Amorosi; David Holmes, Jr. Cost Effectiveness Following Treatment Initiation of Stroke Reduction Strategies in Non-Valvular Atrial Fibrillation: Warfarin vs NOACs vs Left Atrial Appendage Closure. J Am Coll Cardiol. 2016;68(18_S):B251-B252. doi:10.1016/j.jacc.2016.09.758

Vivek Y. Reddy, Ronald L. Akehurst, Shannon O. Armstrong, Stacey L. Amorosi,
Nic Brereton, Deanna S. Hertz, and David R. Holmes Jr. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to Warfarin. European society of Cardiology February 2016

RL. Akehurst, SL Amorosi, S Armstrong. Considerations When Evaluating Cost-Effectiveness Analyses of Novel Stroke Prevention Therapies. J Am Coll Cardiol. 2016;67(18):2194-2195. doi:10.1016/j.jacc.2016.01.078

Hazel Squires, James Chilcott, Ronald Akehurst, Jennifer Burr, Michael P. Kelly: A systematic literature review of the key challenges for developing the structure of public health economic models. Int J Public Health January 2016 (pp 1-10)

Catherine E.Rycroft, PhD, Matthew Hirst,MSc, William C.N.Dunlop, MEc, Olaf, Pirk,MD,PhD, Daniel Mullins, PhD, Ron Akehurst, BSc,DSc. The Suitability of End Point Designs for Health Technology Assessment in Chronic Pain Studies. ViH 18(2015)987 – 9 9 3

Reddy VY, Akehurst RL, Armstrong SO, Amorosi SL, Beard SM, Holmes DR Jr. Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF: Warfarin Versus NOACs Versus LAA Closure. Journal of the American College of Cardiology Dec 2015

B. Pennington, R. Akehurst, H. Wasan, B. Sangro, A. S. Kennedy, K. Sennfält & L. Bester: Cost-effectiveness of selective internal radiation therapy using yttrium-90 resin microspheres in treating patients with inoperable colorectal liver metastases in the UK. JME, Volume 18, Issue 10, 2015

Jha A, Upton A, Dunlop WC, Akehurst R. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. 2015 Aug;32(8):742-56. doi: 10.1007/s12325-015-0233-1

V. Reddy, R. Akehurst, S C Amorosi, S. Armstrong, S. Beard, C.Knight, C. Taggart, D. Holmes: Cost effectiveness of left atrial appendage closure versus Warfarin for stroke risk reduction in non-valvular Atrial Fibrillation in CMS patients
ViH; 18(3): A44 · May 2015

Gareth Morgan, Antonio Palumbo, Sujith Dhanasiri, Dawn Lee, Katja Weisel, Thierry Facon, Michel Delforge, Albert Orio, Mohamed Zaki, Xin Yu, Lars Sternas, Christian Jacques, Ron Akehurst, Fritz Offner and Meletios A. Dimopoulos. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. British Journal of Haematology; Volume 168, Issue 6, pages 820–823, March 2015

Alexander Hirst, Chris Knight, Matt Hirst, Will Dunlop, Ron Akehurst. Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine. Eur J Health Econ DOI 10.1007/s10198-015-0673-1 February 2015. Eur J Health Econ (2016) 17:217–227

Skedgel C, Wailoo A, Akehurst R. Societal preferences for distributive justice in the allocation of health care resources: a latent class discrete choice experiment. Medical Decision Making January 2015

Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL, Campbell MJ. Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method. Statistical Methods in Medical Research, 21 Nov 2014.

Tosh J, Stevenson M, Akehurst R. Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review. October 2014

Brereton N, Pennington B, Ekelund M, Akehurst R. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model. Journal of Medical Economics Sept 2014

Gladwell D, Henry T, Cook M, Akehurst R. Cost Effectiveness of Renal Denervation Therapy for the Treatment of Resistant Hypertension in the UK. Applied Health economics and Health Policy. August 2014

Bradley P, Akehurst R, Callard C, Bannerjee S, Blennow K, Bremner J, Broich K, Cummings J: a multi stakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's Disease. Alzheimer’s and Dementia July 2014

Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H, Van Veldhuisen DJ, Vincent John: Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. Heart 3rd July 2014 Heart doi:10.1136/heartjnl-2014-305673

Cooper, Katy; Matcham, James;Helme, Kawitha; Akehurst, Ron: Update on Romiplostim and Eltrombopag Indirect Comparison. Int J of Tech Assess in Health Care; 2014, 1-2

Bradley P, Akehurst R, Ballard C, Banerjee S, Blennow J, Bremner J, Broich K, Cummings J, Dening K, Dubois B, Klipper W, Leibman C, Mantua V, Molinuevo JL, Morgan S, Muscolo Luisa, Nicolas F, Pani L, Robinson L, Siviero P, Van Dam J, Evan Emelen J, Wimo A, Wortmann M, Goh L. Taking Stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer’s disease. Alzheimer’s and Dementia 2014; 1- 7

Vivek Reddy; Ronald L. Akehurst; Stacey L. Amorosi; Shannon Armstrong; Colin Taggart; Steve Beard; Chris Knight; David Holmes. Cost utility and quality of life impact of left atrial appendage closure compared to warfarin for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2014;63(12_S):. doi:10.1016/S0735-1097(14)60353-3

Nicholas R Latimer, Keith T Abrams, Paul C Lambert, Michael J Crowther, Allan J Wailoo, James P Morden, Ron L Akehurst, Michael J Campbell. Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context. Medical Decision Making January 2014

V.Y. Reddy, R.L. Akehurst, S.L. Amorosi, S. Armstrong, D.R. Holmes. An Analysis of the Cost Effectiveness of Left Atrial Appendage Closure for the Prevention of Stroke in Patients with Atrial Fibrillation and Absolute Contraindications to Warfarin Therapy. Value in Health 2013

Vivek Y Reddy, Ronald L Akehurst, Stacey L Amorosi, Shannon Armstrong and David R Holmes. Cost Effectiveness of Left Atrial Appendage Closure in Atrial Fibrillation Patients With Previous Stroke or Transient Ischemic Attack. American Heart Association 2013

Chris D Skedgel, Allan J Wailoo Ron Akehurst. Choosing Vs Allocating: choice experiments and constant-sum paired comparisons for the elicitation of societal preferences. John Wiley & Sons Ltd Health Expectations May 2013

J J Sandra Kooij, Michael Huss, Philip Asherson, Ron Akehurst, Kathleen Beusterien, Alexis French, Rahul Sasane;Paul Hodgkins: Distinguishing Comorbidity and successful management of Adult ADHD. J of Att Disorders. July 2012 Vol 16 No 5 Supp 3S-19S

H Squires, J Chilcott, R Akehurst, J Burr: Guidance for Modellers for Developing Public Health Economic Models. Lancet Vol 380 S68 2012

J B Pietzsch, B P Geisler, R L Akehurst: PMD23: Long Term Clinical and Cost Effectiveness of Catheter-Based Renal Denervation in the UK: A Model Based Projection Based on the Symplicity HTN2 Trial. Value in Health Vol 15, 7, A349, 2012

Cooper K.L, Fitzgerald P, Dilllingham K, Helme K, Akehurst R: Romiplostim and Eltrombopag for Immune Thrombocytopenia: Methods for Indirect comparison. International Journal of Technology Assessment in Health Care / Volume 28 / Issue 03 / July 2012, pp 249-258 Sept 2012

Geisler B.P, Egan B.M, Cohen J.T, Garner A.M, Akehurst R, Esler M.D, Pietzsch J.B. Cost Effectiveness and Clinical Effectiveness of Catheter Based Renal Denervation for Resistant Hypertension. Journal of the American College of Cardiology, Vol 60;14;2012

Asherson P, Akehurst R, Sandra Kooij JJ, Huss M, Beusterien K, Sasane R, Gholizadeh S, Hodgkins P. Under Diagnosis of Adult ADHD: Cultural Influences and Societal Burden.
Journal of Attention Disorders, vol 16, no 5, sup 20S-38S, July 2012

Kaltenthaler EC, Dickson R, Boland A, Carroll C, Fitzgerald P, Pappaioannou D, Akehurst R A qualitative study of manufacturers’ submissions to the UK NICE single technology appraisal process. BMJ Open 2012;2

N Brereton, B Winn, R Akehurst: The cost effectiveness of celecoxib vs diclofenac in the treatment of Osteoarthritis in the UK: an update to the NICE modelusing data from the CONDOR trial. J Med Econ, Vol 15, No 3, pp 465-472, 2012

Llloyd A, Hodgkins P, Akehurst R, Sonuga-Barke EJS, Fitgerald P, Nixon A, Erder H, Brazier JE. Estimation of utilities in attention-deficit hyperactivity. Patient 4(4):247-57 (2011).

Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011, 11:404.

Madan J, Stevenson MD, Cooper KL, Ades AE, Whyte S, Akehurst R.  Consistency between Direct and Indirect Trial Evidence: Is Direct Evidence Always More Reliable? Value in Health 14 (2011) 953-960.

Akehurst R, Brereton N, Ariely R, Lusa T, Groot M, Foss P, Boonen S.  The cost effectiveness of Zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prioe fractures: evidence from Finland, Norway and the Netherlands. Journal of Medical Economics 2011, Vol 14 (pp53-64).

Akehurst RL. Health Technology Assessment in the United Kingdom. Value in Health 2010, Vol 13, Supplement S1 (ppS4-S5).

Brereton N, Bodger K, Kamm MA, Hodgkins P, Yan S, Akehurst R.  A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. Journal of Medical Economics 2010, Vol 13 (pp148-161).

Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R, Akehurst R, Snowden J.  Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosi: and exploratory cost-effectiveness analysis. Bone Marrow Transplantation 2009. 305.

Stevenson MD, Macdonald MC, Langley J, Hunsche E, Akehurst R.  The Cost-Effectiveness of Bosentan in the United Kingdom for Patients with Pulmonary Arterial Hypertension of WHO Functional Class III. Value in Health. Vol 12 (8): 1100-1105.

Karnon J, Tolley K, Oyee J, Ossa D, Akehurst R. Cost-utility analysis of deferasirox compared to standard therapy with desferriozamine for patients requiring iron chelation therapy in the United Kingdom.  Current Medical Research and Opinion 2008, Vol 24(6): 1609-1621.

Nagy B, Brennan A, Brandtmuller A, Thomas S, Gallagher M, Sullivan S, Akehurst R. Introducing a methodology to use activities of daily living outcomes in the assessment of the cost-effectiveness of Alzheimer's disease treatments: A case study using rivastigmine patch.  Alzheimer's and Dementia 2008. Vol 4(4): 455-455.

Sutcliffe P, Dixon S, Akehurst R, Wilkinson A, Shippam A, White S, Richards R, Caddy C. Evaluation of core surgical procedures for sex reassignment in male-to-female and female-to-male transexuals: a systematic review. Journal of Plastic, Reconstructive and Aesthetic Surgery 2008. Vol 62(3): 294-306.

Kaltenthaler E, Tappenden P, Booth A, Akehurst R.  Comparing methods for full versus single technology apprasial: A case study of docetaxel and paclitaxel for early breast cancer.  Health Policy 87 2008; 389-400.

Karnon J, Brennan A, Akehurst R.  A Critique and Impact Analysis of Decision Modelling Assumptions.  Medical Decision Making 2007, Vol 27(4):491-499.

Culyer AJ, McCabe C, Briggs AH, Claxton K, Buxton M, Akehurst R, Sculpher M, Brazier J. Searching for a threshold, not setting one: the role of the National Institute of Health and Clinical Excellence, Journal of Health Services Research and Policy; 12(1) January 2007: 56-58(3).

Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, Sculpher M, Tsuchyia A Should patients have a greater role in valuing health states? Applied Health Economics and Policy 2005; 4(4): 201-208.

Brennan A, Akehurst R, Davis S, Sakai H, Abbott V (2007). The Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease, Value in Health; 10 (1): 32-41.

Karnon J, Bakhai A, Brennan A, Flather M, Warren E, Gray D, Akehurst R. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK, International Journal of Cardiology; 109(3):307-16.

Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion, Health Economics 2006; 15(1): 1-4.

O´Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, Fenwick E, Fryback D, Sculpher M, Spiegelhalter D, and Willan A. Incorporation of uncertainty in health economic modelling studies. PharmacoEconomics 2005; 23 (6): 529-536.

Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J, O´Hagan A. Probabilistic Sensitivity Analysis for NICE Technology Assessment: Not an Optional Extra. Health Economics 2005; 14(4): 339-347.

Karnon J, Brennan, A, Pandor A, Fowkes G, Lee A, Gray D, Coshall C, Nicholls C, Akehurst R. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK, Current Medical Research and Opinion, 2005; 21(1):101-12.

Postgraduate Students

Nick Latimer
Chris Skedgel
Hazel Squires


Ron Akehurst is based in Health Economics and Decision Science (HEDS)